关注
LUIS GONZAGA PAZ-ARES RODRIGUEZ
LUIS GONZAGA PAZ-ARES RODRIGUEZ
其他姓名Paz-Ares L, Paz-Ares LG, PazAres L
Profesor of Medicine, Complutense University
在 ucm.es 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
97792015
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
89492015
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
60152012
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ...
New England Journal of Medicine 377 (20), 1919-1929, 2017
41112017
Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer
L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ...
New England Journal of Medicine 379 (21), 2040-2051, 2018
32252018
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ...
New England Journal of Medicine 378 (22), 2093-2104, 2018
29772018
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
29752009
Lung cancer: current therapies and new targeted treatments
FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ...
The Lancet 389 (10066), 299-311, 2017
29102017
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ...
New England Journal of Medicine 379 (24), 2342-2350, 2018
26562018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
25292017
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
23192019
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
15972019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
14212020
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ...
The Lancet Oncology 17 (5), 577-589, 2016
12692016
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
12202017
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open …
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
The Lancet Oncology 22 (2), 198-211, 2021
10252021
Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials …
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ...
Journal of clinical oncology 35 (35), 3924-3933, 2017
8752017
Current challenges in cancer treatment
J Zugazagoitia, C Guedes, S Ponce, I Ferrer, S Molina-Pinelo, L Paz-Ares
Clinical therapeutics 38 (7), 1551-1566, 2016
8662016
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non …
L Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, ...
The lancet oncology 13 (3), 247-255, 2012
7772012
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ...
Cancer discovery 3 (4), 406-417, 2013
7762013
系统目前无法执行此操作,请稍后再试。
文章 1–20